ワシントンにおける非ホジキンリンパ腫の臨床試験
ワシントン内の拠点で、非ホジキンリンパ腫に関する20件の研究が参加者を募集しています。
ワシントン内の都市
公式研究テキスト（英語）
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 103, Tacoma
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07582432A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Fred Hutchinson Cancer Research Center, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05006716Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Medical Oncology Associates (Summit Cancer Centers) ( Site 2710), Spokane
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT04728893A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance), Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Swedish Cancer Institute (SCI), Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07101328TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Northwest Medical Specialties, Bonney Lake
- Northwest Medical Specialties, Federal Way
- Northwest Medical Specialties, Gig Harbor
- 他4件
被験者募集中第2相
12歳以上 · 全性別 · 2026/09/22更新 · NCT02693535Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Northwest Medical Specialties, Tacoma
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06806033A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT04104776A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Medical Oncology Associates, PS, Spokane
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05254743A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- Fred Hutch Cancer Center, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/17更新 · NCT06528301Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中第2相
6 Months – 65 Years · 全性別 · 2026/07/22更新 · NCT06013423DALY II USA/ MB-CART2019.1 for DLBCL
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/13更新 · NCT04792489A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Fred Hutchinson Cancer Research Center, Seattle
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- University of Washington Medical Center, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/16更新 · NCT03328078Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Kaiser Permanente Bellevue Medical Center, Bellevue
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- 他5件
被験者募集中観察研究
18歳以上 · 全性別 · 2026/03/17更新 · NCT06418204A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Swedish Cancer Institute, Seattle
被験者募集中第4相
18歳以上 · 全性別 · 2026/03/02更新 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Swedish Cancer Institute, Seattle
被験者募集中第4相
18歳以上 · 全性別 · 2026/03/02更新 · NCT06876649Study of SGR-1505 in Mature B-Cell Neoplasms
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT05544019SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Seattle
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Swedish Cancer Institute, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2025/10/02更新 · NCT05780034ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。